BMRN
$56.05
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
Intraday
Recent News
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally
Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology.
This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally
This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases.
Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy?
HealthEquity delivers cloud-based healthcare savings solutions to employers and individuals, with a broad client network across the U.S.
BioMarin Pharmaceutical (BMRN) Receives FDA Approval for Expanded Use of PALYNZIQ in Adolescents
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best get-rich-quick stocks to buy according to hedge funds. On February 27, the US FDA approved BioMarin’s supplemental Biologics License Application for PALYNZIQ, expanding its use to include adolescents aged 12 and older with phenylketonuria/PKU. This medication remains the only approved enzyme substitution therapy designed to reduce […]
BioMarin Pharmaceutical Highlights Growth Plan, VOXZOGO Milestones, and Amicus Deal at Conference
BioMarin Pharmaceutical (NASDAQ:BMRN) executives highlighted a three-pillar strategy focused on growth, innovation, and “value commitment” during a fireside chat hosted by Leerink Partners’ Joe Schwartz, pointing to recent revenue momentum, multiple clinical milestones, and the planned addition of A